Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab
JAAD International · 2024-09 · 16 · 66-71
DOI: 10.1016/j.jdin.2024.02.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAAD International, 2024-09. Verfasst von Tamara Gracia Cazaña und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Miguel Servet University Hospital, Instituto de Investigación Sanitaria de Aragón, University of Zaragoza, Zaragoza, Spain. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The treatment of psoriasis in patients with a personal history of cancer is a matter of debate and limited evidence is available to guide clinicians.
Objectives
To report a multicenter real-life experience of a group of patients with psoriasis undergoing treatment with guselkumab and a history of cancer.
Methods
We conducted a multicenter retrospective Spanish study enrolling patients with moderate-to-severe plaque psoriasis and neoplasia being treated with guselkumab for their psoriasis.
Results
Twenty patients with moderate-to-severe psoriasis and at least 12 weeks of ongoing treatment were included. For the analysis, a 52 week follow-up period was evaluated in terms of efficacy and safety. Most of the malignancies in these patients were solid tumors. The percentage of patients achieving psoriasis area and severity index ≤3 at week 12 and week 52 was 80% and 87.5%, respectively, whereas 68.8% of patients achieved psoriasis area and severity index ≤1. A 52-week survival rate of 100% in the study population was observed (n = 20), including those patients with concomitant active cancers (n = 14). No adverse effects or dropouts related to guselkumab safety profile were detected.
Limitations
Modest sample size and the retrospective nature of the study.
Conclusion
Guselkumab not only demonstrates high effectiveness in treating psoriasis but also exhibits a favorable safety profile in patients with neoplasms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Miguel Servet University Hospital, Instituto de Investigación Sanitaria de Aragón, University of Zaragoza, Zaragoza, Spain.
- Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
- Department of Dermatology, Basurto University Hospital, Bilbao, Spain.
- Department of Dermatology, Complejo Hospitalario de Navarra, Pamplona, Spain.
- Department of Dermatology, Lozano Blesa University Hospital Zaragoza, Zaragoza, Spain.
- Dermatology Unit, Hospital de Barbastro, Huesca, Spain.
Zitieren
APA
Gracia Cazaña, T., Riera Monroig, J., Izu, R., Yanguas, I., Lorda Espés, M., Sánchez Salas, M. P., García Gil, M. F., Navarro Bielsa, A., Aldea Manrique, B., Almenara Blasco, M., García-Latasa de Araníbar, F. J., Fuentelsaz, V., Morales Callaghan, A., & Ara-Martín, M. (2024). Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab. JAAD International, 16, 66-71. https://doi.org/10.1016/j.jdin.2024.02.019
Vancouver
Gracia Cazaña T, Riera Monroig J, Izu R, Yanguas I, Lorda Espés M, Sánchez Salas MP, et al. Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab. JAAD International. 2024;16:66-71. doi:10.1016/j.jdin.2024.02.019
BibTeX
@article{GraciaCazaa2024,
author = {Gracia Cazaña, Tamara and Riera Monroig, Josep and Izu, Rosa and Yanguas, Ignacio and Lorda Espés, Marta and Sánchez Salas, María Pilar and García Gil, Miguel Fernando and Navarro Bielsa, Alba and Aldea Manrique, Beatriz and Almenara Blasco, Manuel and García-Latasa de Araníbar, Francisco Javier and Fuentelsaz, Victoria and Morales Callaghan, Ana and Ara-Martín, Mariano},
title = {Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab},
journal = {JAAD International},
year = {2024},
volume = {16},
pages = {66--71},
doi = {10.1016/j.jdin.2024.02.019}
}
EUVIMED